Dexcom (DXCM) Cash from Financing Activities (2010 - 2026)

Dexcom (DXCM) has 17 years of Cash from Financing Activities data on file, last reported at -$25.0 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$25.0 million, down 300.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.7 billion (down 137.13% YoY), and the FY2025 annual result was -$1.7 billion, down 129.5% from the prior year.
• Cash from Financing Activities rose to -$25.0 million in Q1 2026 per DXCM's latest filing, from -$1.5 billion in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $939.5 million in Q2 2023 and troughed at -$1.5 billion in Q4 2025.
• A 5-year average of -$195.1 million and a median of -$1.7 million in 2025 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities soared 21948.84% in 2023, then slumped 95037.5% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at -$1.0 million in 2022, then tumbled by 63090.0% to -$631.9 million in 2023, then soared by 99.75% to -$1.6 million in 2024, then tumbled by 95037.5% to -$1.5 billion in 2025, then surged by 98.36% to -$25.0 million in 2026.
• Business Quant data shows DXCM's Cash from Financing Activities at -$25.0 million in Q1 2026, -$1.5 billion in Q4 2025, and -$175.0 million in Q3 2025.